STA Research assigns a Speculative Buy rating, and sets the 12 month target at $3.00 per share.
According to the projections made by 3 market experts regarding the stock price of Biofrontera Inc stock (BFRI stock price), the average analyst target price for Biofrontera Inc stock is $11.33 for the next 12 months. The average rating given by analysts to Biofrontera Inc stock is Buy. Based on 0 positive signals and 4 negative signals, Stock Target Advisor’s very own stock analysis of Biofrontera Inc. indicates a Very Bearish outlook for the company’s stock. The stock price of Biofrontera Inc. was USD 1.99 as of the most recent market close. Over the course of the last week, the price of Biofrontera Inc.’s stock has decreased by 0.10 percent, while over the course of the last month it has increased by 0.89 percent, and over the course of the last year it has remained unchanged.
Biofrontera Inc., a biopharmaceutical company based in the United States, is in the business of marketing pharmaceuticals that are used in the treatment of dermatological conditions. The company offers the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. Additionally, the company offers Ameluz, a prescription medication that is approved for use in conjunction with the company’s licensor’s medical device. Both of these products can be purchased through the company’s website. In addition to that, it has the medicated cream Xepi that is prescribed for the treatment of impetigo. The company was established in 2015, and its headquarters are currently located in Woburn, Massachusetts.
What we like:
There is no fundamental attribute that we can detect on the stock that would warrant a positive outlook. The stock is a pure speculative play!
What we don’t like:
Low market capitalization is something that we do not appreciate.
This company’s market capitalization is below the sector’s median, which places it among the smaller entities in its industry. In the long run, this may make it less stable, but only if it does not have a distinctive technology or market that can assist it in growing or being acquired in the future.
When compared to its book value, the price is too high.
On the basis of price to book value, the stock is trading at a high level in comparison to the median of its peers.
Cash flow that is negative
The most recent four quarters of the company’s operations resulted in a negative total cash flow.
Slow Increase in Earnings
When compared to other companies in its industry over the past five years, this stock’s earnings growth has been significantly lower than the sector’s median.